Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cerevel Therapeutics Holdings Inc

Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer in a multi-billion dollar deal.

Cerevel options trading surge before AbbVie deal news raises eyebrows

AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Humira faces a raft of new competition.

AbbVie to buy drug developer Cerevel for $8.7 billion

AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's “robust” neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion AbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CT NORTH CHICAGO, Ill.

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

Enterprise Products Partners

Innovative Industrial Properties

Public Storage

AT&T

Tyson Foods

Watsco

As investors, we always strive to build a well-balanced portfolio that can provide stability through various economic cycles. While high-flying growth stocks generate all the hype these days (and deservedly so), defensive dividend stocks remain essential to provide a steady stream of income, as well as stability.

7 High-Dividend Stocks to Buy for a Lifetime of Passive Income

AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc , a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.

Exclusive: AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources

Coca-Cola

In the sections below, we discuss why we believe KO will offer higher returns than ABBV in the next three years.

Down 10% This Year Is Coca-Cola Stock A Better Pick Over AbbVie?

Collaboration to leverage BigHat's Artificial Intelligence and Machine Learning (AI/ML) guided Milliner™ platform and AbbVie's expertise in Oncology and Neuroscience to develop next-generation antibodies BigHat to receive $30 million upfront payment with potential for further milestone payments and royalties NORTH CHICAGO, Ill. and SAN MATEO, Calif.

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

ImmunoGen

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ImmunoGen, Inc. (NasdaqGS: IMGN) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of ImmunoGen will receive $31.26 in cash for each share of ImmunoGen that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whet.

IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN

AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price. The acquisition provides AbbVie with a commercial-stage company and a flagship drug that generated $105 million in sales in Q3. Let's look at this massive acquisition's "behind the curtain" benefits.

AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition

Altria

Philip Morris

Verizon

High-yield dividend stocks can be a red flag, but not always. Four companies in the S&P 500 offer huge dividends.

5 S&P 500 Stocks That Pay a Generous Dividend

AbbVie has announced its acquisition of ImmunoGen for $10.1 billion in cash, marking a strategic move amidst rising competition for their leading treatment, Humira. ImmunoGen's Elahere, part of the innovative class of antibody-drug conjugates (ADC), specifically targets cancer cells, offering potential benefits in reducing toxicity for surrounding cells.

AbbVie bolsters portfolio with $10.1 billion ImmunoGen buyout for cancer therapy

Alector Inc

Amylyx Pharmaceuticals

Athira Pharma

Coya Therapeutics Inc

GlaxoSmithKline

Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive functions, motor functions, or sometimes both.

These biotechs targeting multiple neurodegenerative diseases

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

AbbVie Inc has announced the acquisition of ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash - a deal that takes into the world of antibody-drug conjugates (ADC), which target cancer cells more precisely, potentially reducing harm to healthy cells. The deal is part of AbbVie's strategy to diversify its portfolio as its best-selling drug, Humira, faces increasing competition, but it also throws the spotlight on other companies working on ADC technology.

Abbvie's $10bn swoop puts the spotlight on antibody-drug conjugates stocks

The pharmaceutical sector veteran announced its latest major asset buy. It has agreed to purchase one of its peers.

Why Abbvie Stock Popped Today

Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.

AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study

Other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of AbbVie's buyout of ImmunoGen.

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie (ABBV) agreed to buy the rival biotech firm for $10.1 billion to expand its cancer drug portfolio.

AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie's ex-Humira growth products showed solid growth in Q3, boosting management's confidence in their success. The company upgraded its guidance, raised its full-year revenue estimates, and adjusted its EPS outlook. AbbVie stock has been impacted by industry rotation and macroeconomic headwinds, but its profitability grade supports confidence in a subsequent recovery.

AbbVie: Get Ready For More Painful Downside

Apple

AMC Entertainment

Amazon

Salesforce

Altamira Therapeutics Ltd

Disney

GameStop

Unlimited HFND Multi-Strategy Return Tracker ETF

Microsoft

Nutanix

NVIDIA

Pure Storage

RedHill Biopharma

Snowflake

Tesla

Ulta Beauty

Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 a share.

AbbVie to Acquire ImmunoGen in $10 Billion Deal

AbbVie has consistently been one of the best-performing Dividend Kings over the past 10 years. With its flagship drug in decline, however, the company's shares have faltered in 2023.

AbbVie Should Consider a Dividend Cut -- Here's Why

AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market for cancer treatments.

News for AbbVie Stock (ABBV)